Evidence map›Paper›PMID 41861772›Full record

ArticleThe journal of prevention of Alzheimer's disease2026

Characteristics of infusion-related reactions to lecanemab in early Alzheimer's disease: A multicenter real-world study in Northwestern China.

Peijie Liu, Jie Liu, Jin Wang, Ying Du, Zhirong Liu, Hong Zhang, Aiqin Zhu, Gejuan Zhang, Xinling Meng, Chunmei Zhao and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of prevention of Alzheimer's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Peijie LiuDepartment of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Jie LiuDepartment of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Jin WangDepartment of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Ying DuDepartment of Neurology, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Zhirong LiuDepartment of Neurology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Hong ZhangDepartment of Neurology, Shaanxi Provincial People's Hospital, Xi'an, China.
Aiqin ZhuDepartment of Geriatrics, Qinghai Provincial People's Hospital, Xining, China.
Gejuan ZhangDepartment of Neurology, The Affiliated Hospital of Northwest University, Xi'an No.3 Hospital, Xi'an, China.
Xinling MengDepartment of Neurology, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi, China.
Chunmei ZhaoDepartment of Neurology, General Hospital of Ningxia Medical University, Yinchuan, China.
Weiping ZhangDepartment of Neurology, Xi'an Central Hospital, Xi'an, China.
Liangjun DangDepartment of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Wei ZhangDepartment of Neurology, Tangdu Hospital, Air Force Medical University, Xi'an, China. Electronic address: tdzw@fmmu.edu.cn.
Qiumin QuDepartment of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: quqiumin@xjtufh.edu.cn.
Yan QuDepartment of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: quyan1178@xjtufh.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfusion-related reactions (IRRs) represent the most common adverse events associated with lecanemab. However, real-world data on IRR characteristics and risk factors in Asian populations, particularly Chinese, remain scarce.

methodsIn a multicenter prospective registry, 139 patients with early Alzheimer's disease (AD) receiving lecanemab were included. IRRs were physician-confirmed. Multivariable logistic regression identified independent predictors.

resultsThe cumulative IRR incidence was 12.36 %, highest at the first infusion (17.3 %) and decreased significantly thereafter (P < 0.001). Fever (54.2 %) and dizziness (16.7 %) were the most common symptoms. 45.8 % of IRRs occurred 2-24 hours after infusion. All IRRs were mild (Grade 1) and self-limited. Hypertension (OR = 5.017, P = 0.007) and higher Fazekas score (OR = 2.734, P = 0.017) were independently associated with IRR. DISCUSSION: In this Chinese real‑world cohort, lecanemab‑associated IRRs were less frequent, mild, and delayed. Hypertension and white‑matter hyperintensity severity emerged as key risk factors, underscoring the potential role of cerebrovascular health in IRR susceptibility.

Indexed as

Alzheimer DiseaseAgedAged, 80 and overChinaFemaleHumansHypertensionIncidenceMaleProspective StudiesRegistriesRisk FactorsAlzheimer’s diseaseInfusion-related reactionLecanemabReal-world studyRisk factors

Identifiers

PMID41861772
PMCPMC13010427

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.